Enhanced detection of target DNA by fragment size analysis
A fragment and size technology, applied in the field of circulating tumor DNA, can solve unmet problems
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0177] Characteristic fragments of tumor cfDNA: 1 Example
[0178] Using 344 plasma samples and additional samples from 65 healthy control plasma from 18 different types of cancer, 200 patients suffering from fragmentation produces directory feature cfDNA ( figure 1 with figure 2 A). Compared with healthy individuals, cancer patients cfDNA fragment size distribution of 90 to 150bp, 180 to 220bp and 320bp within the size range of 250 to different ( figure 2 B and image 3 ). Plasma of healthy individuals and patients with advanced glioma, the size of the patient's plasma fragment cfDNA kidney, pancreas and bladder cancer is significantly higher than other types of advanced cancers, including breast cancer, ovarian cancer, lung cancer, melanoma, cholangiocarcinoma, colorectal cancer, and longer (p figure 2 C). According to the classification cfDNA 150bp fragment ratio in the size range of 20 to 18 types of cancers and Bettegowda et al. CtDNA sorting performed by measuring the concent...
Embodiment 2
[0179] Example 2: mutant measure ctDNA
[0180] Two highly specific method for determining the size spectrum of plasma mutant ctDNA. First, we inferred ctDNA and non-tumor cfDNA sWGS from mouse plasma by carrying human ovarian carcinoma xenografts particular dimensions of the spectrum ( Figure 4 A). ctDNA fragment size shift (Shift) to less than 167 bp ( Figure 4 B). Second, patients having deep sequencing analysis of specific hybridization capture group selected from the group exon whole outer matched tumor samples developed to determine the size of mutant spectra in plasma ctDNA 19 cancer patients ( Figure 4 C). > 300 × cfDNA depth of hundreds of mutations by sequencing, allele-specific reads obtained from the mutant and normal DNA. Observed tumor-bearing mutant alleles of the enriched DNA fragment (fragment in size than the nucleosomal DNA (167bp multiples) is short of about 20 to 40bp Figure 4 D). Mutant ctDNA usually more than the non-mutant fragment of cfDNA, which has a max...
Embodiment 3
[0181] Select tumor-derived DNA fragments: Example 3
[0182] These data indicate ctDNA shorter than non-tumor cfDNA, and show differences in biological fragment length may be utilized to improve the detection ctDNA. In 48 plasma samples from 35 patients with high-grade serous ovarian cancer (HGSOC) is using in vitro selection using a bench size microfluidic device is followed to determine the feasibility of shorter fragments sWGS selective sequencing ( Image 6 A, Figure 7 with Figure 8 ). Use accuracy and quality assessment of the size of selected plasma from 20 healthy individuals ( Image 6 B and Figure 9 ). SWGS also uses data from untreated positioning reads explore the utility of the DNA fragment of the size of the selected machine ( Image 6 A). By selecting the 90 to 150bp fragment length within a size range corresponding to the paired-end reads, reads once the reference genome than the size selection of the machine proceeds. Image 6 C, Image 6 D and Image 6 E illustrates th...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More